Memorial Sloan Kettering Cancer Center, United States
N/A
(1551550) PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition
Friday, October 6, 20238:20 AM – 8:30 AM EDT
(1548587) Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Sunday, October 8, 202312:35 PM – 12:40 PM EDT
